High-throughput T-cell receptor sequencing reveals shared immune signatures in celiac disease, opening the door to earlier, less invasive diagnosis and disease monitoring.
Researchers develop gluten-degrading enzymes to administer as drugs or incorporate into food and explore therapies that block downstream disease checkpoints.